EchoPlus3
Research type
Research Study
Full title
Improving Pulmonary Congestion Assessment in Heart Failure with Preserved Ejection Fraction\n
IRAS ID
290346
Contact name
John McMurray
Contact email
Sponsor organisation
NHS Greater Glasgow and Clyde
Clinicaltrials.gov Identifier
NA, NA
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
This study aims to understand the importance of findings on lung ultrasound of patients with known heart failure and preserved ejection fraction (HFpEF). This is important as treatment of HFpEF is primarily focused on volume regulation and early detection of congestion to prevent decompensation and hospitalisation. The hypothesis is lung ultrasound is superior to current markers of volume overload and incorporating its use in assessment of patients with HFpEF could improve quality of life and reduce hospitalisations. 600 patients will be involved, with 175 from Queen Elizabeth University Hospital (Glasgow) catchment. All participants will be recruited by a clinical research fellow. There will be two other sites recruiting in Boston and Nashville. Participants will be identified from symptomatic ambulant patients with known or suspected HFpEF attending outpatient services for clinical review or for clinically indicated echocardiogram and have either been hospitalised with heart failure or have an elevated NTproBNP. If eligible, written informed consent will be obtained and participants will undergo an initial study visit. They will have a detailed medical history and physical examination conducted including a record of current symptoms and drug therapies, weight and vital signs. A blood sample will be obtained for NTproBNP, a blood marker of heart failure. Participants will be asked to complete a questionnaire on quality of life and rate their shortness of breath on a scale. An echocardiogram and lung ultrasound will be performed. Virtual follow up of patients by review of clinical notes will inform of subsequent hospital admissions or death.\nThis study will provide vital information regarding prevalence of lung ultrasound changes in patients with HFpEF and how this correlates with echocardiogram finding, quality of life, biomarkers and prognosis. The results will inform the development of a simple clinical congestion risk score which can be used to guide treatment.\n
REC name
South Central - Oxford B Research Ethics Committee
REC reference
21/SC/0226
Date of REC Opinion
29 Jul 2021
REC opinion
Further Information Favourable Opinion